Neurotrophic effects of growth/differentiation factor 5 in a neuronal cell line

Neurotoxicity Research

Volumn 21, Issue 3, 2012, Pages 256-265

  Toulouse, André ^a   Collins, Grace C ^a   Sullivan, Aideen M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

6 hydroxydopamine; Growth differentiation factor 5; Neurotrophin; Parkinson's disease; SH SY5Y cells

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 5; OXIDOPAMINE; SMAD PROTEIN;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR TRANSPORT; NERVE CELL; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTROPISM; PRIORITY JOURNAL;

BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOPAMINERGIC NEURONS; GENE EXPRESSION; GROWTH DIFFERENTIATION FACTOR 5; HUMANS; NEUROBLASTOMA; OXIDOPAMINE; PARKINSON DISEASE; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SIGNAL TRANSDUCTION; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 84861459292     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-011-9266-7     Document Type: Article

References (44)

1. 2 in chromaffin cells. Eur J Pharmacol 293:55-64
2. Akerud P, Alberch J, Eketjall S et al (1999) Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J Neurochem 73:70-78 (Pubitemid 29289112)
3. Bartus RT (2009) CERE-120 (AAV2-NTN) for Parkinson's Disease: Review of Progress and Future Plans. American Society of Cell and Gene Therapy Meeting, San Diego
4. Berk AJ, Sharp PA (1977) Sizing and mapping of early adenovirus mRNAs by gel electrophoresis of S1 endonuclease-digested hybrids. Cell 12:721-732 (Pubitemid 8224412)
5. Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211 (Pubitemid 36007810)
6. Castelo-Branco G, Sousa KM, Bryja V et al (2006) Ventral midbrain glia express region-specific transcription factors and regulate dopaminergic neurogenesis through Wnt-5a secretion. Mol Cell Neurosci 31:251-262 (Pubitemid 43214535)
7. Clayton KB, Sullivan AM (2007) Differential effects of GDF5 on the medial and lateral rat ventral mesencephalon. Neurosci Lett 427:132-137 (Pubitemid 47633800)
8. Cookson MR (2005) The biochemistry of Parkinson's disease. Annu Rev Biochem 74:29-52 (Pubitemid 40995500)
9. Gasmi M, Brandon EP, Herzog CD et al (2007a) AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: longterm efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 27:67-76 (Pubitemid 46921475)
10. Gasmi M, Herzog CD, Brandon EP et al (2007b) Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 15:62-68 (Pubitemid 46043650)
11. Gill SS, Patel NK, Hotton GR et al (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-595 (Pubitemid 36597106)
12. Glinka Y, Gassen M, Youdim MB (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl 50:55-66 (Pubitemid 27055928)
13. Gomez-Santos C, Ambrosio S, Ventura F et al (2002) TGF-beta1 increases tyrosine hydroxylase expression by a mechanism blocked by BMP-2 in human neuroblastoma SH-SY5Y cells. Brain Res 958:152-160 (Pubitemid 35441223)
14. Herzog CD, Dass B, Holden JE et al (2007) Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 22:1124-1132 (Pubitemid 47067222)
15. Horger BA, Nishimura MC, Armanini MP et al (1998) Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18:4929-4937 (Pubitemid 28285401)
16. Hurley FM, Costello DJ, Sullivan AM (2004) Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease. Exp Neurol 185:281-289 (Pubitemid 38084854)
17. Kordower JH, Herzog CD, Dass B et al (2006) Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60:706-715 (Pubitemid 46048488)
18. Krieglstein K, Suter-Crazzolara C, Hotten G et al (1995) Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons. J Neurosci Res 42:724-732
19. Lin LF, Doherty DH, Lile JD et al (1993) GDNF: a glial cell linederived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132 (Pubitemid 23186789)
20. Liu Y, Rubin B, Bodine PV et al (2008) Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J Cell Biochem 105:497-502
21. Lopes FM, Schroder R, Junior ML et al (2010) Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res 1337:85-94
22. Marks WJ, Verhagen Metman L, Starr PA, et al (2006) Trophic factor gene transfer in Parkinson's disease: preliminary outcomes from the phase I CERE-120 study. American Neurological Association, 131st Annual Meeting, Chicago, IL
23. Mastroeni D, Grover A, Leonard B et al (2009) Microglial responses to dopamine in a cell culture model of Parkinson's disease. Neurobiol Aging 30:1805-1817
24. Mayhew TM (1992) A review of recent advances in stereology for quantifying neural structure. J Neurocytol 21:313-328
25. McMillan CR, Sharma R, Ottenhof T et al (2007) Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells. Neurosci Lett 419:202-206 (Pubitemid 46755488)
26. Michel PP, Hefti F (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26:428-435 (Pubitemid 20261989)
27. Nishitoh H, Ichijo H, Kimura M et al (1996) Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem 271:21345-21352 (Pubitemid 26292996)
28. O'Keeffe GW, Dockery P, Sullivan AM (2004a) Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro. J Neurocytol 33:479-488 (Pubitemid 40768572)
29. O'Keeffe GW, Hanke M, Pohl J et al (2004b) Expression of growth differentiation factor-5 in the developing and adult rat brain. Brain Res Dev Brain Res 151:199-202 (Pubitemid 38887747)
30. Pahlman S, Ruusala AI, Abrahamsson L et al (1984) Retinoic acidinduced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ 14:135-144 (Pubitemid 14089031)
31. Pahlman S, Hoehner JC, Nanberg E et al (1995) Differentiation and survival influences of growth factors in human neuroblastoma. Eur J Cancer 31A:453-458
32. Patel NK, Bunnage M, Plaha P et al (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57:298-302 (Pubitemid 40179870)
33. Rosenberg PA (1988) Catecholamine toxicity in cerebral cortex in dissociated cell culture. J Neurosci 8:2887-2894
34. Sammar M, Stricker S, Schwabe GC et al (2004) Modulation of GDF5/BRI-b signalling through interaction with the tyrosine kinase receptor Ror2. Genes Cells 9:1227-1238 (Pubitemid 39618536)
35. Sammar M, Sieber C, Knaus P (2009) Biochemical and functional characterization of the Ror2/BRIb receptor complex. Biochem Biophys Res Commun 381:1-6
36. Slevin JT, Gerhardt GA, Smith CD et al (2005) Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell linederived neurotrophic factor. J Neurosurg 102:216-222 (Pubitemid 43194069)
37. Storch A, Kaftan A, Burkhardt K et al (2000) 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J Neural Transm 107:281-293 (Pubitemid 30162690)
38. Storch A, Ludolph AC, Schwarz J (2004) Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration. J Neural Transm 111:1267-1286 (Pubitemid 39468390)
39. Sullivan AM, Opacka-Juffry J, Hotten G et al (1997) Growth/ differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease. Neurosci Lett 233:73-76 (Pubitemid 27418167)
40. Sullivan AM, Pohl J, Blunt SB (1998) Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur J Neurosci 10:3681-3688 (Pubitemid 29073925)
41. Sullivan AM, Opacka-Juffry J, Pohl J et al (1999) Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration. Brain Res 818:176-179 (Pubitemid 29227300)
42. ten Dijke P, Miyazono K, Heldin CH (2000) Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem Sci 25:64-70 (Pubitemid 30100368)
43. Toulouse A, Sullivan AM (2008) Progress in Parkinson's diseasewhere do we stand? Prog Neurobiol 85:376-392
44. Wood TK, McDermott KW, Sullivan AM (2005) Differential effects of growth/differentiation factor 5 and glial cell line-derived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain. J Neurosci Res 80: 759-766 (Pubitemid 40961287)